Most Popular Angioplasty Web Site
supported by Volcano Corporation
Volcano Receives CE Mark for iFR Scout Pullback Software to Help Diagnose Serial Lesions and Diffuse Coronary Disease
Share This Story:
Bookmark and Share

external sites:
Philips Healthcare

March 12, 2015 -- Amsterdam, the Netherlands and San Diego -- Royal Philips (NYSE: PHG; AEX: PHIA), today announced that Volcano, a Philips business, has received CE Mark for the iFR Scout pullback software, a functional extension of its existing iFR Modality, optimized to assess serial lesions and diffuse coronary disease. Limited Market Release will commence immediately at leading European and Japanese medical centers. This software is currently pending 510(k) clearance at the US FDA. It is not available for sale in the US.

The iFR Modality is a physiologic measurement performed using the same Volcano pressure measurement guide wires and equipment used by catheterization labs for Fractional Flow Reserve (FFR), but it avoids the administration of hyperemic agents into the patient that induce stress to the heart to increase blood flow. This allows for a meaningful, lesion-specific assessment in seconds by amplifying the signal at rest. The iFR Modality is currently installed on over 2,000 systems worldwide.

Physicians have historically used a pressure wire pullback technique with FFR, under hyperemic conditions, to assess the type of underlying disease severity, whether focal or diffuse, to help determine the appropriate treatment for the patient. With the iFR Scout pullback software, this same functionality to 'scout out' the most treatable lesions will now be available without the administration of a hyperemic agent, thereby potentially reducing procedural time and cost to the facility, as well as improving patient comfort.

Dr. Javier Escaned
Dr. Javier Escaned

"Up to now, many operators felt uncomfortable in the frequent scenario of FFR interrogation in vessels with more than one stenosis, as interpretation is more difficult due, and intravenous infusion is mandatory for FFR pullbacks," stated Dr. Javier Escaned, Consultant Interventional Cardiologist at Hospital Clνnico San Carlos, Madrid, Spain. "The great attractiveness of iFR pullback is that resting flow is much more constant, and stable in these cases, allowing for more predictable interpretation of results. Further, we will now be able to conduct pullback without the need for administration of hyperemic agents. This may contribute to a wider adoption of physiological vessel mapping and, therefore, to a better, tailored treatment of patients with multiple coronary stenoses."

"The iFR Scout release represents another innovative step forward in making coronary physiology faster, and simpler, so that more patients worldwide can benefit from the value that physiology-guided treatment brings over angiography alone," commented Joe Burnett, General Manager Image Guided Therapy Devices at Volcano, a Philips business. "Globally, more than 2,000 systems have been activated with iFR, truly surpassing our expectations for adoption of this novel technology. Our teams are very excited to bring the iFR Scout capability to institutions so that clinicians can see first-hand the value that physiologic pullback provides in helping guide appropriate treatment to patients with serial stenoses, diffuse disease and other challenging clinical scenarios."

Source: Philips Healthcare